NEW YORK (AP) — In a story September 29, 2020, which included information about Myovant Sciences’ potential prostate cancer drug, The Associated Press erroneously reported that the drug failed to meet multiple goals in a study. The drug failed to meet one of its goals within a broader late-stage study.
Copyright © 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.